

The invention is directed to compounds of Formula (I), described herein, as well as pharmaceutically acceptable salts thereof, which act as CRF₁ antagonists and are useful in the treatment of disorders and diseases associated with CRF₁ receptors, including CNS- related disorders and diseases.